The diagnostics technology developer has raised another $290m from existing investor Roche, which will support it as it looks to expand its products to additional cancers.
Pharmaceutical firm Roche invested $290m in US-based cancer detection technology developer Freenome on Tuesday, roughly a month after it announced its $300m series D round.
Founded in 2014, Freenome has developed a multiomics platform which combines molecular biology and machine learning to detect cancer in the early stages through a routine blood draw by decoding complex cell-free biomarker patterns.
The company’s series D round was co-led by Perceptive Advisors and RA Capital Management and included internet and technology conglomerate…
